Welcome to the Lilly Scientific Information Page for AD/PD 2026
Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Copenhagen, Denmark
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To stay informed on the latest science and innovation from Lilly Medical, please be sure to follow us on LinkedIn
Disclosures
TUESDAY
- Disease State: Parkinson's Disease
- Presented by: Ajay Kurani
- Molecule(s): Not Applicable
EMERGING CEREBELLOTHALAMIC CONNECTIVITY CORRELATES WITH TREMOR IN EARLY PARKINSON’S DISEASE
Trial(s) Overview:
Not Applicable
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Nalin Payakachat
- Molecule(s): Not Applicable
ESTIMATING THE PREVALENCE OF ELEVATED PLASMA P-TAU217 AMONG COGNITIVELY UNIMPAIRED INDIVIDUALS AGED 55 TO 79 YEARS IN THE US
Trial(s) Overview:
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Drew Spargo
- Molecule(s): Not Applicable
COST-EFFECTIVENESS OF CONFIRMATORY BLOOD TESTING TO IDENTIFY AMYLOID PATHOLOGY IN PATIENTS WITH COGNITIVE IMPAIRMENT IN THE UNITED STATES
Trial(s) Overview:
Not Applicable
TUESDAY
- Disease State: Alzheimer's Disease
- Presented by: Vikas Kotari
- Molecule(s): Flortaucipir F18
TIME TO REGIONAL TAU POSITIVITY – A NOVEL APPROACH FOR ASSESSING LONGITUDINAL TAU ACCUMULATION AND TREATMENT RESPONSE
Trial(s) Overview:
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Oskar Hansson
- Molecule(s): Not Applicable
OPTIMIZING DIAGNOSTIC WORKFLOWS FOR ACCURATE DETECTION OF STAGE 1–2 (PRECLINICAL) ALZHEIMER’S DISEASE
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Harun Noristani
- Molecule(s): Not Applicable
CEREBRAL AMYLOID ANGIOPATHY TRIGGERS DISTINCT COMPLEMENT COMPONENT 4 ACTIVATION IN HUMAN: AN IN-DEPTH SPATIAL OMIC STUDY
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Niraj Patel
- Molecule(s): Not Applicable
THE DIAGNOSIS AND MANAGEMENT OF ALZHEIMERS DISEASE: REAL-WORLD INSIGHTS FROM ENGLAND
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Juan Maldonado Wang
- Molecule(s): Not Applicable
MAPPING INFLAMMATION: SPATIAL OMICS REVEALS VASCULAR SIGNATURES IN ALZHEIMER’S DISEASE
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Drew Spargo
- Molecule(s): Donanemab
BASELINE CHARACTERISTICS AMONG EARLY INITIATORS OF DONANEMAB IN THE UNITED STATES: A REAL-WORLD STUDY
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Ann Hartry
- Molecule(s): Donanemab
DEMOGRAPHIC, COGNITIVE, AND BIOMARKER PATTERNS IN MCI AND ALZHEIMER’S DISEASE (AD) AMONG PATIENTS INITIATING DONANEMAB IN THE REAL-WORLD
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Xavier Taylor
- Molecule(s): Not Applicable
UNRAVELING THE IMMUNOLOGICAL AND VASCULAR CASCADE TRIGGERED BY AMYLOID IMMUNOTHERAPY
Trial(s) Overview:
Not Applicable
FRIDAY
- Disease State: Alzheimer's Disease
- Presented by: Sergey Shcherbinin
- Molecule(s): Donanemab
AMYLOID TRAJECTORIES AFTER DONANEMAB TREATMENT: 3-YEAR DATA FROM TRAILBLAZER-ALZ 2
Trial(s) Overview:
FRIDAY
- Disease State: Alzheimer's Disease
- Presented by: Ivelina Gueorguieva
- Molecule(s): Donanemab
DONANEMAB EXPOSURE-RESPONSE (AMYLOID PLAQUE) MODEL INCLUDING TRAILBLAZER-ALZ 6 AND LONG-TERM OFF-TREATMENT DATA FROM TRAILBLAZER-ALZ 2
Trial(s) Overview:
FRIDAY
- Disease State: Alzheimer's Disease
- Presented by: Matan Dabora
- Molecule(s): Remternetug
SCREENING AND BASELINE CHARACTERISTICS IN TRAILRUNNER-ALZ 3: A PHASE 3 CLINICAL TRIAL INVESTIGATING SUBCUTANEOUS REMTERNETUG IN ALZHEIMER’S DISEASE STAGES 1-3
Trial(s) Overview:
FRIDAY
- Disease State: Dementia with Lewy Bodies
- Presented by: Kevin Biglan
- Molecule(s): Donanemab
TRAILBLAZER-ALZ 7: A PHASE 2 STUDY EVALUATING DONANEMAB IN SYMPTOMATIC INDIVIDUALS WITH MCI AND ALPHA-SYNUCLEIN AND AMYLOID CO-PATHOLOGY
Trial(s) Overview:
TRAILBLAZER-ALZ 7
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)